News
BRIBF
0.231
NaN%
--
Weekly Report: what happened at BRIBF last week (0908-0912)?
Weekly Report · 09/15 10:31
Weekly Report: what happened at BRIBF last week (0901-0905)?
Weekly Report · 09/08 10:33
Weekly Report: what happened at BRIBF last week (0825-0829)?
Weekly Report · 09/01 10:29
Weekly Report: what happened at BRIBF last week (0818-0822)?
Weekly Report · 08/25 10:36
Brii Biosciences reports 1H results
Seeking Alpha · 08/21 16:47
Weekly Report: what happened at BRIBF last week (0811-0815)?
Weekly Report · 08/18 10:31
Weekly Report: what happened at BRIBF last week (0804-0808)?
Weekly Report · 08/11 10:36
Weekly Report: what happened at BRIBF last week (0728-0801)?
Weekly Report · 08/04 10:38
Weekly Report: what happened at BRIBF last week (0721-0725)?
Weekly Report · 07/28 10:39
Weekly Report: what happened at BRIBF last week (0714-0718)?
Weekly Report · 07/21 10:32
Weekly Report: what happened at BRIBF last week (0707-0711)?
Weekly Report · 07/14 10:38
Weekly Report: what happened at BRIBF last week (0630-0704)?
Weekly Report · 07/07 10:33
Weekly Report: what happened at BRIBF last week (0623-0627)?
Weekly Report · 06/30 10:37
Weekly Report: what happened at BRIBF last week (0616-0620)?
Weekly Report · 06/23 10:32
Weekly Report: what happened at BRIBF last week (0609-0613)?
Weekly Report · 06/16 10:36
Weekly Report: what happened at BRIBF last week (0602-0606)?
Weekly Report · 06/09 10:37
Weekly Report: what happened at BRIBF last week (0526-0530)?
Weekly Report · 06/02 10:43
Weekly Report: what happened at BRIBF last week (0519-0523)?
Weekly Report · 05/26 10:43
Weekly Report: what happened at BRIBF last week (0512-0516)?
Weekly Report · 05/19 10:36
Weekly Report: what happened at BRIBF last week (0505-0509)?
Weekly Report · 05/12 10:36
More
Webull provides a variety of real-time BRIBF stock news. You can receive the latest news about Brii Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About BRIBF
Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.